



6 January 2021

AIM: RENE.L

RNS REACH

ReNeuron Group plc
("ReNeuron" or the "Company")

Analyst Conference Call

ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, will host a conference call for analysts at 10.00am GMT today to discuss the Company's recent half year results, fundraising and outlook for the year ahead.

Analysts who require dial-in details, please contact Buchanan at reneuron@buchanan.uk.com.

A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 6 January 2021 at this link:

<https://webcasting.buchanan.uk.com/broadcast/5fd23c59ca22cd76f9d3c662>

The recorded webcast will also be made available at the investor centre of ReNeuron's website, <http://www.reneuron.com/investors/investor-centre/>.

ENQUIRIES:

ReNeuron Olav Hellebø, Chief Executive Officer Michael Hunt, Chief Financial Officer	+44 (0) 20 3819 8400
Buchanan (UK Media/Investor relations) Mark Court, Sophie Wills, Tilly Abraham	+44 (0) 20 7466 5000
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	+44 (0) 20 7710 7600
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Hannah Woodley	+44 (0) 20 7496 3000

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com